News

Will 100% coverage spur more use of breast cancer chemopreventives?

Publish date: January 22, 2014

 

On Twitter @aliciaault

Pages

Recommended Reading

Veliparib-carboplatin combo is first 'graduate' of I-SPY2 trial
MDedge Internal Medicine
Meeting attendees identify top studies presented at SABCS
MDedge Internal Medicine
'Vogl, New York' offers San Antonio perspectives
MDedge Internal Medicine
Add-on agents boost neoadjuvant chemo response in triple-negative disease
MDedge Internal Medicine
Breast MRI screening finds undetected cancers in 11 per 1,000 average-risk women
MDedge Internal Medicine
Findings set stage for immunomodulatory approaches in breast cancer
MDedge Internal Medicine
Exercise protects black women against ER-negative breast cancer
MDedge Internal Medicine
Primary care screening advised to select women for BRCA counseling
MDedge Internal Medicine
No overall benefit seen with bisphosphonate treatment in chemoresistant breast cancer
MDedge Internal Medicine
Survival no better after primary tumor removal in metastatic breast cancer
MDedge Internal Medicine